ABOUT KoPERM/ISPE

The Korean Society for Pharmacoepidemiology and Risk Management (KoPERM) is determined to contribute to the improvement of national health through research into matters related to drug safety, including collecting, analyzing, and evaluating its domestic/foreign information and sharing that information with its members, thus making policy proposals for drug safety and its risk management.

Government organizations, academic authorities, and commercial industries in Korea used to work independently toward the same objectives, and so they were not systematically connected or able to contribute substantially to the creation of an efficient drug safety management system on the national level. Therefore, KoPERM, as a new organization, intends to generate a synergy effect by bringing together the efforts of related stakeholders. It currently has approximately 500 members and hosts annual spring and fall academic conferences to establish an effective overall drug safety management system.

 

The International Society for Pharmacoepidemiology (ISPE) is a non-profit international professional membership organisation dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy; education; and advocacy for the field of pharmacoepidemiology, including pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management.

ISPE convenes an International Conference on Pharmacoepidemiology each year, as well as a regional Conference on Pharmacoepidemiology in Asia. The purpose of these meetings is to discuss key issues in pharmacoepidemiology through plenaries, podium presentations and posters as well as symposia where experts address topics of interest in the field. A preliminary day is also scheduled in which educational sessions are available at both basic and more advanced levels. These meetings offer an excellent opportunity for networking and social interaction with colleagues engaged in pharmacoepidemiology in Government, industry and academia.